Your browser doesn't support javascript.
loading
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Chen, Robert; Zinzani, Pier Luigi; Lee, Hun Ju; Armand, Philippe; Johnson, Nathalie A; Brice, Pauline; Radford, John; Ribrag, Vincent; Molin, Daniel; Vassilakopoulos, Theodoros P; Tomita, Akihiro; von Tresckow, Bastian; Shipp, Margaret A; Lin, Jianxin; Kim, Eunhee; Nahar, Akash; Balakumaran, Arun; Moskowitz, Craig H.
Afiliación
  • Chen R; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
  • Zinzani PL; Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "Seràgnoli" University of Bologna, Bologna, Italy.
  • Lee HJ; Department of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX.
  • Armand P; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.
  • Johnson NA; Department of Hematology, Jewish General Hospital, Montreal, QC, Canada.
  • Brice P; Department of Hematology-Oncology, Hopital Saint Louis, Paris, France.
  • Radford J; Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Ribrag V; Department of Drug Development and Hematology, Institut Gustave Roussy, Villejuif, France.
  • Molin D; Section of Experimental and Clinical Oncology, Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
  • Vassilakopoulos TP; Department of Hematology and Bone Marrow Transplantation, General Hospital of Athens, Athens, Greece.
  • Tomita A; Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan.
  • von Tresckow B; Department of Internal Medicine, University of Cologne and University Hospital of Cologne, Cologne, Germany.
  • Shipp MA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.
  • Lin J; Medical Oncology, Merck & Co, Inc, Kenilworth, NJ; and.
  • Kim E; Medical Oncology, Merck & Co, Inc, Kenilworth, NJ; and.
  • Nahar A; Medical Oncology, Merck & Co, Inc, Kenilworth, NJ; and.
  • Balakumaran A; Medical Oncology, Merck & Co, Inc, Kenilworth, NJ; and.
  • Moskowitz CH; Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL.
Blood ; 134(14): 1144-1153, 2019 10 03.
Article en En | MEDLINE | ID: mdl-31409671
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2019 Tipo del documento: Article